

Financial Results for 3Q(Nine months) of FYE 3/2021

February 10th, 2021 STELLA CHEMIFA CORPORATION

Securities code: 4109

Index



(Financial Results)

[Reference Material]

(Corporate Profile • Introduction of Our Business)

- Performance Highlights
- P. 3

Corporate Profile

P. 17

Financial Summary

P.4 - 11

Subsidiaries & Associates P. 1

Financial Forecast

P. 12 - 14

• Introduction of Our Business P. 19-33

Shareholder Return

P. 15

Performance Highlights



[3Q(Nine months) of FYE 3/2021 Results]

- Semiconductors and LCDs saw increased shipments to domestic market and other areas including Taiwan, albeit with lower shipments to South Korea.
- ◆ Shipments of enriched boron (10B) used by nuclear energy-related facilities contributed to the profit.
- Profitability improved in the Medical Business owing to the launch of sales of pharmaceuticals and curbed expenses.

[Full-year Forecast]

- Business environment remains strong mainly in Semiconductors and LCDs business.
- ◆ Price of anhydrous hydrofluoric acid(AHF) has started to rise since the end of 2020 although it remained at low level in 3Q.

Financial Summary



(million yen)	3Q (Nine months) of FYE 3/2020	3Q (Nine months) of FYE 3/2021	Increase/ Decrease	Percentage Increase/ Decrease
Sales Revenue	24,731	24,927	196	0.8
Gross Profit	4,843	6,022	1,178	24.3
Operating Profit	1,649	2,902	1,252	75.9
Ordinary Profit	1,611	2,763	1,152	71.5
Quarterly Profit Attributable to Owners of Parent	1,094	1,975	881	80.5
Earnings Per Share (yen)	84.76	153.99		
Capital Expenditures	2,652	1,245	-1,406	-53.0
Depreciation & Amortization	2,426	2,296	-130	-5.4
Research & Development Expenses	1,121	587	- 534	-47.6

Sales Revenue and Operating Profit by Business Segment




		Sales Rever	nue			Operating P	rofit	
	3Q (Nine months)	3Q (Nine months)	Incre Decr		3Q (Nine months)	3Q (Nine months)	Incre Decre	
(million yen)	of FYE 3/2020	of FYE 3/2021	Amount	%	of FYE 3/2020	of FYE 3/2021	Amount	%
High-Purity Chemical Business	21,249	21,619	370	1.7	2,008	3,041	1,032	51.4
Transportation Business	3,293	2,985	-307	-9.3	379	421	42	11.1
Medical Business	-	155	155	-	-768	-482	285	-
Other	188	166	-22	-11.8	24	17	-7	-31.1
Eliminations and Corporate	-	-	-	-	5	– 94	-100	-
Total	24,731	24,927	196	0.8	1,649	2,902	1,252	75.9

Beyond the Chemical

Sales Revenue of High-Purity Chemical Business (Breakdown)




(million yen)	3Q (Nine months) of FYE 3/2020	3Q (Nine months) of FYE 3/2021	Increase/ Decrease	Percentage Increase/ Decrease
Surface Treatment	1,135	722	-412	-36.4
Alternatives for CFCs	3,001	3,324	323	10.8
Batteries	1,933	1,659	- 273	-14.2
Semiconductors/ LCDs	11,908	12,214	305	2.6
Semiconductor Devices	330	519	188	56.9
Catalysts	701	634	-67	-9.6
Gypsum	126	146	19	15.4
General Products	1,377	1,688	311	22.6
Other	732	709	-23	-3.2
Total	21,249	21,619	370	1.7






Analysis of Operating Profit (Year on year)





Change of Quarterly Operating Profit






		FYE 3/2019			FYE 3/2020			FYE 3/2021				
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Sales Revenue	10,134	9,323	9,275	9,649	9,733	7,406	7,591	8,998	8,222	8,389	8,315	
Operating Profit	949	1,209	727	636	847	148	653	757	884	902	1,116	
Operating Profit Margin	9.4%	13.0%	7.8%	6.6%	8.7%	2.0%	8.6%	8.4%	10.8%	10.8%	13.4%	

Transitions in Trade Statistics Value of Anhydrous Hydrofluoric Acid






(yen/kg)	FYE 3/2017	FYE 3/2018	FYE 3/2019	FYE 3/2020	FYE 3/2021
Average Price	135	209	220	186	163

Source: Prepared by our company based on the Ministry of Finance's "Trade Statistics of Japan" (http://www.customs.go.jp/toukei/info/)

Change of Shipping Volume of High-Purity Hydrofluoric Acid (Semiconductors and LCDs)





Balance Sheet



(million yen)	FYE 3/2020 End-of-Year	Dec.31,2020	Increase/ Decrease	Percentage Increase/ Decrease
Assets	53,216	52,064	-1,152	-2.2
Cash and deposits	13,591	13,786	194	1.4
Operating receivables	8,137	9,559	1,421	17.5
Inventory assets	5,495	4,658	-837	-15.2
Property, plant, and equipment	22,794	21,719	-1,075	-4.7
Intangible assets	655	547	-107	-16.4
Liabilities	18,487	16,306	-2,181	-11.8
Operating liabilities	3,310	2,929	-380	-11.5
Interest-bearing liabilities	11,184	9,439	-1,745	-15.6
Net Assets	34,729	35,758	1,029	3.0
Equity capital	34,033	35,153	1,119	3.3
Liabilities and Net Assets	53,216	52,064	-1,152	-2.2

Financial Forecast



* Released on Nov.6.2020

					011 11001.0.2020
(million yen)	FYE 3/2021 Initial Forecast	FYE 3/2021 Revised Forecast*	Increase/ Decrease	Percentage Increase/ Decrease	FYE 3/2020 Actual
Sales Revenue	33,300	32,200	-1,100	-3.3	33,729
Operating Profit	1,900	3,150	1,250	65.8	2,407
Ordinary Profit	1,950	3,100	1,150	59.0	2,307
Profit Attributable to Owners of Parent	1,400	2,150	750	53.6	1,924
Earnings Per Share (yen)	108.41	167.61			149.00
Dividend (yen)	45	45	-	-	45
ROE (%)	4.0	6.2	2.2	55.0	5.8
Capital Expenditures	2,250	1,950	-300	-13.3	3,694
Depreciation & Amortization	3,130	3,020	-110	-3.5	3,236
Research & Development Expenses	1,560	870	-690	-44.2	1,513

Forecast on Sales Revenue and Operating Profit by Business Segment



* Released on Nov.6.2020

	Sales Revenue					Operatir	ng Profit	
(million yen)	FYE 3/2021 Initial Forecast	FYE 3/2021 Revised Forecast*	Percentage Increase/ Decrease	FYE 3/2020 Actual	FYE 3/2021 Initial Forecast	FYE 3/2021 Revised Forecast*	Percentage Increase/ Decrease	FYE 3/2020 Actual
High-Purity Chemical Business	28,670	27,880	-2.8	29,058	2,420	3,500	44.6	2,897
Transportation Business	4,420	3,900	-11.8	4,429	510	490	-3.9	502
Medical Business	-	200	-	-	-1,050	- 760	-	-1,035
Other	210	220	4.8	241	20	20	-	36
Eliminations and Corporate	-	-	-	-	-	-100	-	7
Total	33,300	32,200	-3.3	33,729	1,900	3,150	65.8	2,407

Beyond the Chemical

Forecast on Sales Revenue of High-Purity Chemical Business (Breakdown)



* Released on Nov.6.2020


	* Released 01					
(million yen)	FYE 3/2021 Initial Forecast	FYE 3/2021 Revised Forecast*	Increase/ Decrease	Percentage Increase/ Decrease	FYE 3/2020 Actual	
Surface Treatment	1,300	900	-400	-30.8	1,525	
Alternatives for CFCs	4,500	4,200	-300	-6.7	4,872	
Batteries	2,290	1,980	-310	-13.5	2,576	
Semiconductors/ LCDs	15,700	16,300	600	3.8	15,687	
Semiconductor Devices	460	650	190	41.3	446	
Catalysts	900	780	-120	-13.3	925	
Gypsum	160	160	-	-	201	
General Products	2,590	2,060	-530	-20.5	1,835	
Other	770	850	80	10.4	988	
Total	28,670	27,880	- 790	-2.8	29,058	

Shareholder Return



Stella Chemifa's basic policy is to provide stable and continuous dividend payments, giving comprehensive consideration to factors including its financial condition and profit level. Retained earnings will be allocated to capital investment and R&D investment, and will be proactively utilized for future business development to enhance corporate value.

- ◆ FYE 3/2020
- Annual dividend: 45 yen per share
- ◆ FYE 3/2021
- Annual dividend forecast: 45 yen per share
- The Company repurchased 100,000 of its own shares, worth 260 million yen, in the first half of the current fiscal year.





Reference Material

(Corporate Profile • Introduction of Our Business)

Corporate Profile



(as of December 31, 2020)

Corporate Name	STELLA CHEMIFA CORPORATION
Head Office	Meiji Yasuda Seimei Osaka Midosuji Bldg. 10F, 4-1-1 Fushimi-machi, Chuo-ku, Osaka City, Osaka
Founded/Established	February 1916 / February 1944
Capital Fund	4,829,782,512 yen
Representatives	Representative Director, President and Chief Executive Officer: Aki Hashimoto Representative Director, Senior Managing Executive Officer (Products Management Group): Kiyonori Saka
U R L	https://www.stella-chemifa.co.jp/english/
Number of Employees	298
Sales Department	Osaka Sales Department (Chuo-ku, Osaka city, Osaka) Tokyo Sales Department (Chiyoda-ku, Tokyo)
Factory	Sanpo Factory (Sakai-ku, Sakai City, Osaka) Izumi Factory (Izumiotsu City, Osaka) Kitakyushu Factory (Yahatanishi-ku, Kitakyushu City, Fukuoka)

Subsidiaries & Associates



At home (3 companies)


Transportation Business	BLUE EXPRESS, Inc.	Sakai-ku, Sakai City, Osaka
Other Business	BLUE AUTO TRUST Co., Ltd.	Sakai-ku, Sakai City, Osaka
Medical Business	STELLA PHARMA CORPORATION	Chuo-ku, Osaka city, Osaka

Abroad (7 companies)

High-Purity Chemical Business	STELLA CHEMIFA SINGAPORE PTE LTD	Singapore
Transportation Business	STELLA EXPRESS (Singapore) PTE LTD	Singapore
High-Purity Chemical Business	Blue Express (Shanghai) International Trade Inc.	China
Transportation Business	Blue Express (Shanghai) International Freight Forwarding Co., Ltd.	China
High-Purity Chemical Business	Zhejiang Blue Star Chemical Co., Ltd.	China
High-Purity Chemical Business	FECT CO.,LTD	South Korea
High-Purity Chemical Business	Quzhou BDX New Chemical Materials Co., Ltd.	China



Manufacture and applications of hydrogen fluoride



Beyond the Chemical



High-Purity Chemical Business

Surface Treatment	Manufacture and sale of chemicals used for acid cleaning of stainless steel and slimming of LCD panels	
Alternatives for CFCs	Manufacture and sale of hydrofluoric anhydride, raw materials for CFCs and fluoropolymers	
Batteries	Manufacture and sale of additives to improve the performance of lithium-ion secondary batteries	
Semiconductors/LCDs	Manufacture and sale of chemicals for etching and cleaning in the semiconductor and LCD panel manufacturing processes	
Semiconductor Devices	Manufacture and sale of raw materials for camera and stepper lenses, tantalum production aids for tantalum capacitors, etc.	
Catalysts	Manufacture and sale of raw materials for fluoropolymers and catalysts for the manufacture of pharmaceutical intermediates, etc.	
G y p s u m	Sale as raw material for concrete, etc. (Byproduct of hydrofluoric acid production)	
General Products	Manufacture and sale of fluorine compounds for toothpaste, concentrated boron compounds, etc.	
O t h e r	Sales of purchased goods, etc.	

- Semiconductors/LCDs -



Ultra-High Purification Technology

- Impurity levels of less than 1 ppt (1×10⁻¹²) are controlled by ultra-purification and ultra-cleaning technologies
- Mass production of ultra-pure chemicals for ultra-high integrated circuit


Ultra High Purity Hydrofluoric Acid	 Hydrofluoric acid (HF) is the only chemical capable of etching out silicon oxide film Chemical solutions are indispensable to the semiconductor manufacturing process and require ultra-high purity In particular, dilute hydrofluoric acid is used in a number of semiconductor processes
Ultra High Purity Buffered Hydrofluoric Acid	 Mixed aqueous solution of hydrofluoric acid (HF) and ammonium fluoride (NH₄F) Mainly used in processes such as etching and cleaning of insulation films Chemicals with etch rates ranging from tens of Å/min to thousands of Å/min can be produced


Example of Application (Photolithography Process)


(1) Photoresist coating on silicon wafer (heat drying)

Photoresist
Silicon oxide film


Silicon substrate











- Semiconductors/LCDs -



Production capacity of High Purity Hydrofluoric Acid for Semiconductors

Kitakyushu Factory



30,000 t /year

Sanpo Factory



65,000 t /year

STELLA CHEMIFA SINGAPORE



10,000 t /year

105,000 t /year

* As a comprehensive manufacturer of fluorine compounds, we use our own technology to do everything from manufacturing to filling.

- Batteries -

Additives

- Additive for electrolytic solution to improve the performance of lithium-ion secondary batteries
- High-temperature endurance · High conductivity ·
 Increased capacity · Low resistance · Flame retardance

Lithium Hexafluorophosphate

High-purity electrolytes for lithium-ion secondary batteries

* Manufacturing at our affiliate company in China (Maximum production capacity: 1,300 t/year)





Izumi Factory's manufacturing building (Izumiotsu City, Osaka)

Example of materials used in lithium-ion secondary batteries Additives Positive and negative electrode Separator Current collector Protective IC PTC element

Action on the Development of Materials for the Next-Generation Battery



Quzhou BDX New Chemical Materials Co., Ltd. (China)

[Metal-ion secondary batteries] High-purity electrolytes for sodium-ion secondary batteries

(sodium hexafluorophosphate)

[All-solid secondary batteries] Fluoride materials for all solid-state batteries

[Fluoride-ion secondary batteries] Fluoride-ion conductor material

Beyond the Chemical

- Enriched Boron -





Enrichment plant (Izumiotsu City, Osaka)

Enriched Boron (Boron-10) and its features

- Natural boron is made up of two isotopes, boron-10(20%) and boron-11(80%)
- Developed technology to enrich boron-10 to over 95%
- Established mass production technology of enriched boron for the first time in Japan(2000)
- Boron-10 has an extremely high capacity to absorb neutrons, and further enriching it can increase its ability to absorb neutrons.

Production capacity

Products		Production Capacity (Kg/Year)	Degree of Concentration (wt%)
Enriched Boron	¹⁰ B	3,000	Over 96%
Enriched Boric Acid	H ₃ ¹⁰ BO ₃	20,000	96%
Enriched Potassium tetrafluoroborate K ¹⁰ BF ₄		40,000	96%

- Enriched Boric Acid -



Applications of Enriched Boron Compounds

- Neutron-absorbing material of spent nuclear fuel transportation and storage containers
- Material of control rods of nuclear reactors and rack material of spent nuclear fuel pools
- Excess reaction control of pressurized-water reactors by dissolving into primary cooling water
- Water source for facilities responding to specific major accidents, etc.
- Raw material for cancer treatment drugs (BNCT: Boron Neutron Capture Therapy)

Advantages of Using Enriched Boric Acid

- (1) Improvement of corrosive environment in nuclear reactors

 Required ¹⁰B concentration can be secured at 1/5 of natural products.

 Operation at low concentration is possible, and corrosion in facilities can be reduced.
- (2) Reduction of storage costs

 Heat retention are required to maintain the dissolution of boric acid water.

 Enriched boric acid realizes the reduction in concentration, and reduces the problem of heat retention.
 - In addition, the storage tank can be made smaller.
- (3) More reliable control
 In the event of an emergency stop, more reliable control is possible, and since boric acid is harmful to the human body and the environment, the reduction of overall amount of boric acid is an advantage.

- GMP-related -



Tin Fluoride

2017

The GMP inspection by USFDA for tin fluoride, an active ingredient of OTC anticaries drugs, was completed, and obtained official approval.

2018

Started marketing of "tin fluoride" as a GMP-compliant product.



Izumi Factory's manufacturing building (Izumiotsu City, Osaka)

<Actions of fluorine on teeth>

- To suppress Streptococcus mutans from producing acid (Cavity prevention)
- To promote tooth remineralization
- To form acid-resistant teeth (to form fluorapatite)
- * We expect to see big demand mainly in Europe and the US, where there is strong interest in dental health and beauty.

* What is FDA?

FDA stands for Food and Drug Administration in the U.S. (A public agency, similar in function to the Ministry of Health, Labour and Welfare in Japan)

* What is GMP?


It stands for "Good Manufacturing Practice", which refers to a common standard for manufacturing and quality control of drugs and quasi-drugs.

- New Initiatives -



Phosphor-related Materials

- Development of highly efficient and long-life fluoride phosphor materials using our core technologies.
- Use of the materials is expected to increase in display applications such as mini-LED



Mini-LED is expected to be adopted for in-vehicle displays and meter panels, driving the number of mini-LED displays installed

- New Initiatives -




PCB Materials (Low Dielectric Constant Materials)

 As materials for high-frequency communication devices, used as additives (fillers) to resin and other materials for substrates.


Contribute to suppression of signal transmission loss, miniaturization of devices, and suppression of power

consumption.



Source: Yano Research Institute

Market Forecast on 5G High-frequency Circuits, Substrates, etc.



Filler for suppression of <u>dielectric loss</u> (transmission loss inside the substrate)



Electronic substrate built in highspeed communication devices



Appearance of developed filler

Low dielectric constant Low dielectric tangent

- Other product examples -





Optical Material-Related

- **◆**Calcium Fluoride ◆ Magnesium Fluoride
- ◆Aluminum Fluoride
 - **♦**Zinc Fluoride
- **◆**Lithium Fluoride
- **◆**Lead Fluoride

◆ Potassium Hexafluorotitanate

- ◆Strontium Fluoride
- ◆Barium Fluoride

Reactive Catalyst-Related

- ◆High Purity Boron Trifluoride
- ◆Boron Trifluoride n-Butyl Ether
- ◆Boron Trifluoride Piperidine

- ◆Boron Trifluoride Diethyl Ether
- ◆Boron Trifluoride Phenol
- ◆Triethylamine 3HF

- ◆Boron Trifluoride Dimethyl Ether
- ◆Boron Trifluoride Monoethyl Amine

(Product information)

Surface Treatment, Alternatives for CFCs-Related

◆Anhydrous Hydrofluoric Acid

◆55% Hydrofluoric Acid

Nuclear Energy-Related

- ◆ ¹⁰B Enriched Potassium Fluoroborate
- ◆ ¹⁰B Enriched Boric Acid

Other Products

- ◆Fluorosilicic Acid
- ◆ Copper Fluoroborate
- ◆Ammonium Hydrogenfluoride ◆Sodium Fluoride
- ◆ Potassium Hexafluorozirconate
- ◆ Potassium Hexafluorophosphate
- ◆Potassium Fluorosilicate ◆Fluoroboric Acid
- **♦**Lead Fluoroborate

- ◆Sodium Fluoroborate
- ◆Potassium Fluoride
- **◆**Tin Fluoroborate
- ◆ Potassium Fluoroborate
- ◆Ammonium Fluoride
- ◆ Refined Calcium Fluoride

Newly-Developed Products

- ◆ Detergents Contributing to Increase in Chemical Lifetime
- ◆ Detergents Suppressing Etching of Silicon Nitride Film
- ◆ Detergents Inhibiting Silicon and Polysilicon Damage
- ◆ Battery-Related (Ionic Liquids, Additives for Lithium-Ion Batteries,…etc)
- ◆ Various Fluoride Nanoparticles Dispersant (Magnesium, Lithium, Ytterbium, Calcium)
 - ◆Phosphor materials

- ◆ Nuclear Energy Industry
- ◆Special-Purpose Inorganic Fluorine Compounds
- ♦5G/6G (Information Communication Systems), Printed Circuit Board
 - ◆Fluorinated Carbon Nano-Tubes







* For details, please visit the website.

街のなかでもステラケミファ



病院のなかでもステラケミファ



家のなかでもステラケミファ



学校のなかでもステラケミファ



- Transportation Business -



(HP URL)



Transportation Business

BLUE EXPRESS, Inc.

Transport	Land transport · Marine transport · Rail transport	
Customs Clearance	Customs clearance · Loading and Unloading	
Warehousing	Providing multi-functional warehouses fully equipped with the latest systems	
Container services	Supplying large and pressurized containers that meet ISO specifications, medium-size IBC pressurized containers, as well as IBC containers with UN specifications, and also offering services for cleaning, repairing and leasing the containers	

Customs clearance sites	Shipping terminals	Overseas Bases
Ohama Office	Sendai Office	Singapore
Osaka Office	Kanto Office	China(Shanghai)
Yokohama Office	Yokohama Office	
	Shimizu Office	
	Nagoya Office	
	Ohama Office	
	Kobe Office	
	Kitakyushu Office	



- Medical Business -



Medical Business


STELLA PHARMA CORPORATION

Boron Neutron Capture Therapy

(Boron Neutron Capture Therapy: BNCT)

Mechanism of BNCT

A particle beam treatment that selectively destroys cancer cells by using the nuclear fission reaction between boron (Boron-10) and thermal neutrons produced by injecting a boron agent into cancer cells and irradiating the affected area with neutrons from outside the body.



Boron preparation for BNCT "Steboronine"



[Product name] Steboronine Intravenous Drip Bag 9000 mg/300 mL

[Launch] May 20, 2020

[Regulatory classification] Prescription drugs *Used with a prescription from a doctor, etc.

[Indications] Unresectable locally-advanced or locally recurrent head and neck cancers

- Medical Business -



Medical Business

STELLA PHARMA CORPORATION


Efforts to Expand the Indications

Brain tumor (recurrent malignant glioma)	A phase II study is underway. (Under the consultation of the Prioritized Review System for innovative medicines [SAKIGAKE Designation System])

Recurrent high-grade A physician-led phase II study is underway. meningioma (A Physician-led study)


¹⁸FBPA-PET Initiative

Boron-10 compound (BPA) labeled with ¹⁸F



Visualizing the distribution of Boron-10 compound (BPA) expands the scope of development to include cancers with limited clinical research experience





33